Evidence map›Paper›PMID 41843154›Full record

ArticleCancer immunology, immunotherapy : CII2026

Association of CCL21

Xueying Li, Desi Chen, Yepeng Guo, Gaowei Huang, Zijian Cai, Ting Xue, Zhaohui Chen, Hui Han, Zaishang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xueying Li *Department of Medical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518107, Guangdong, People's Republic of China.
Desi Chen *Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.
Yepeng Guo *Department of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.
Gaowei HuangDepartment of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.
Zijian CaiDepartment of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.
Ting XueState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Zhaohui ChenDepartment of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China.
Hui HanState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. hanhui@sysucc.org.cn.
Zaishang LiDepartment of Urology, Shenzhen People's Hospital, The Second Clinic Medical College of Jinan University, Shenzhen, 518107, Guangdong, People's Republic of China. lizaishang2017@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2025A1515010257Shenzhen People's Hospital Clinical Scientist Cultivation Project SYWGSJCYJ202405Shenzhen Science and Technology Innovation Commission Outstanding Youth Basic Research Project RCYX20221008093032008
6 · The paper itself

Abstract

Penile squamous cell carcinoma (PSCC) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Tertiary lymphoid structures (TLSs) can support antitumour immunity, yet TLS maturation and maturation-associated stromal determinants in PSCC remain unclear. Here, we integrated hematoxylin and eosin (H&E) staining, multiplex immunohistochemical (mIHC) colocalization, spatial transcriptomics, single-cell RNA sequencing (scRNA-seq), and bulk RNA sequencing (bulk RNA-seq) to profile TLS maturity and TLS-associated stromal-immune features in PSCC. TLS maturity was quantified using an AUCell germinal centre-like signature, and the presence of mature TLSs (mTLSs) coincided with improved survival. We identified a CCL21

Indexed as

B-LymphocytesCancer-Associated FibroblastsCarcinoma, Squamous CellChemokine CCL21Penile NeoplasmsTertiary Lymphoid StructuresHumansMaleTumor MicroenvironmentCCL21 protein, humanChemokine CCL21B-cell recruitmentCCL21+ cancer-associated fibroblastsCCL21–CCR7 axisPenile squamous cell carcinomaTertiary lymphoid structures

Identifiers

PMID41843154
PMCPMC12996513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.